MedTrace Logo

Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

NCT03410407 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2022-10-26

No results posted yet for this study

Summary

The present study aims at evaluating the prognostic factors at diagnosis predicting Central Nervous System (CNS) relapse in order to identify a group of patients with higher risk of CNS involvement in which prophylaxis with liposomal Ara-C or other drugs should be indicated.

Conditions

Interventions

OTHER

Observation of CNS involvement

AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Alessandro Pulsoni · Dipartimento di Biotecnologie Cellulari ed Ematologia, "Sapienza", Università di Roma

  • Livio Pagano · Dipartimento di Biotecnologie Cellulari ed Ematologia, "Sapienza", Università di Roma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-19
Primary Completion
2020-06-05
Completion
2020-06-05

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03410407 on ClinicalTrials.gov